@dansfera: Thinking that an FDA Adcom waiver is a golden ticket for your biotech stock? Think again! 🤯 That 'all clear' signal only means the drug dodged the initial novelty or major safety flags. Serious investors know the game doesn't stop there—technical hurdles, like outlier data, or even manufacturing details can still derail the train. Learn why ignoring those less-glamorous risks leads to over-optimism and how to properly gauge the real approval odds for that company you're watching. Don't get caught off guard by the fine print! #BiotechInvesting #FDA #StockMarketTips #PharmaRisk #DueDiligence